Based on the key indicators related to Oramed Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Oramed Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Oramed Pharmaceuticals' Net Debt is relatively stable compared to the past year. As of 11/24/2024, Accounts Payable is likely to grow to about 822.2 K, while Non Current Liabilities Total is likely to drop slightly above 4.2 M. Key indicators impacting Oramed Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Oramed Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Oramed Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Oramed Pharmaceuticals.
Net Income
5.8 Million
Oramed
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Cash Conversion Cycle
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Financing Activities
End Period Cash Flow
Depreciation
Stock Based Compensation
Investments
Issuance Of Capital Stock
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Common Stock Shares Outstanding
Other Stockholder Equity
Total Liab
Common Stock
Total Assets
Net Debt
Accounts Payable
Cash
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Total Current Assets
Accumulated Other Comprehensive Income
Short Long Term Debt Total
Property Plant And Equipment Net
Non Current Assets Total
Non Currrent Assets Other
Short Term Debt
Short Term Investments
Net Receivables
Inventory
Current Deferred Revenue
Capital Lease Obligations
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Capital Stock
Non Current Liabilities Other
Net Working Capital
Selling General Administrative
Other Operating Expenses
Operating Income
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Depreciation And Amortization
Interest Expense
Ebit
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Gross Profit
Cost Of Revenue
Net Interest Income
Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Minority Interest
Probability Of Bankruptcy
Understanding current and past Oramed Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Oramed Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Oramed Pharmaceuticals' assets may result in an increase in income on the income statement.
Oramed Pharmaceuticals competes with Capricor Therapeutics, Akari Therapeutics, Soleno Therapeutics, Bio Path, and Moleculin Biotech. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. Oramed Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Foreign Associate
Israel
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Oramed Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Oramed Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Oramed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Oramed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oramed Pharmaceuticals competition to find correlations between indicators driving Oramed Pharmaceuticals's intrinsic value. More Info.
Oramed Pharmaceuticals is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Oramed Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oramed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Oramed Pharmaceuticals Systematic Risk
Oramed Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oramed Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Oramed Pharmaceuticals correlated with the market. If Beta is less than 0 Oramed Pharmaceuticals generally moves in the opposite direction as compared to the market. If Oramed Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oramed Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oramed Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Oramed Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Oramed Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oramed Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oramed Pharmaceuticals growth as a starting point in their analysis.
Oramed Pharmaceuticals November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oramed Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oramed Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oramed Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Oramed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oramed Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.